CN Patent

CN113292537B — 激酶抑制剂的盐类及其组合物

Assigned to Handa Cancer Medicine Co ltd · Expires 2024-04-05 · 2y expired

What this patent protects

本发明是有关激酶抑制剂C 8 ‑C 16 脂肪基硫酸盐及其组合物。

USPTO Abstract

本发明是有关激酶抑制剂C 8 ‑C 16 脂肪基硫酸盐及其组合物。

Drugs covered by this patent

mobocertinib-succinate (MOBOCERTINIB SUCCINATE)

Patent Metadata

Patent number: CN113292537B
Jurisdiction: CN
Classification: —
Expires: 2024-04-05
Drug substance claim: No
Drug product claim: No
Assignee: Handa Cancer Medicine Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.